BWAY trades 45.0% below Wall Street's consensus target of $19.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BWAY achieves its forward estimates and maintains a stable P/E multiple of 43.9x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, BrainsWay Ltd. (BWAY) has a Wall Street consensus price target of $19.50, based on estimates from 8 covering analysts. With the stock currently trading at $13.45, this represents a potential upside of +45.0%. The company has a market capitalization of $528M.
Analyst price targets range from a low of $19.00 to a high of $20.00, representing a 5% spread in expectations. The median target of $19.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BWAY trades at a trailing P/E of 37.4x and forward P/E of 43.9x. Analysts expect EPS to grow -35.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $4.46, with bear and bull scenarios of $2.81 and $5.87 respectively. Model confidence stands at 56/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 STIMNeuronetics, Inc. | $200M | $2.88 | $5.00 | +73.6% | Buy | — | 7 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 LIVNLivaNova PLC | $4.2B | $77.16 | $88.50 | +14.7% | Buy | 17.7x | 15 |
 GKOSGlaukos Corporation | $9.1B | $153.49 | $190.75 | +24.3% | Buy | — | 25 |
 ELMDElectromed, Inc. | $228M | $27.57 | $48.50 | +75.9% | Buy | 22.7x | 5 |
 ABTAbbott Laboratories | $180.3B | $103.53 | $121.50 | +17.4% | Buy | 18.8x | 41 |
 MDTMedtronic plc | $114.7B | $89.30 | $98.00 | +9.7% | Buy | 14.9x | 51 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
Quick answers to the most common questions about buying BWAY stock.
The consensus Wall Street price target for BWAY is $19.5, representing 45.0% upside from the current price of $13.45. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BWAY has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $19.5 implies 45.0% upside from current levels.
At a forward P/E of 43.8539x, BWAY trades at a premium valuation. The consensus price target of $19.5 (45.0% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $20 for BWAY, while the most conservative target is $19. The consensus of $19.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $6 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BWAY is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BWAY stock forecast based on 8 Wall Street analysts shows a consensus price target of $19.5, with estimates ranging from $19 (bear case) to $20 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $4, with bear/bull scenarios of $3/$6.
Our quantitative valuation model calculates BWAY's fair value at $4 (base case), with a bear case of $3 and bull case of $6. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 56/100.
BWAY trades at a forward P/E ratio of 43.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 37.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BWAY, with a "Buy" consensus rating and $19.5 price target (45.0% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BWAY analyst price targets range from $19 to $20, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19.5 consensus represents the middle ground. Our model's $3-$6 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.